Blocking of inhibitory receptors, such as programmed death-1 (PD-1) or cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), on T-cells, or their ligands on tumor or adjacent T-cells, potentiates anti-tumor responses. This evidence concerns the gene CTLA4 and neoplasm.